Ethical Aspects of Psychedelic-Assisted Treatments: An Overview.

Christopher Poppe, Dimitris Repantis
{"title":"Ethical Aspects of Psychedelic-Assisted Treatments: An Overview.","authors":"Christopher Poppe, Dimitris Repantis","doi":"10.1007/7854_2024_533","DOIUrl":null,"url":null,"abstract":"<p><p>In this chapter, we provide an overview of ethical aspects of psychedelic-assisted treatments in the areas of clinical ethics, research ethics, and at the intersection of psychedelic medicine and society. In contrast to earlier psychedelic research, nowadays medical ethics have been firmly established as a discipline regulating patient-physician relationships which highlight the importance of autonomy, shared decision-making and informed consent in clinical ethics. During and after altered states of consciousness, autonomy is particularly important as participants are in a vulnerable state. In this vulnerable state, both touch and suggestibility are central ethical concerns. In turn, the debate surrounding hallucinogenic and nonhallucinogenic psychedelic substances discusses the importance of altered states of consciousness in general. Of further concern are exceptional training requirements and competencies of psychedelic therapists, as well as the particular context of end-of-life care. Lastly, this section discusses how ethical integrity in clinical treatments can be supported through institutions. In research ethics, inclusivity, research equipoise, and expectation management are key issues in the participation and trials, while open question for the posttrial access to care after psychedelic trials remain. Finally, the chapter addresses the question of equitable access to psychedelic medicine. Furthermore, justice for indigenous communities using psychedelics and the impact of legalization and medicalization of psychedelic substances are pressing ethical concerns amidst the \"psychedelic renaissance.\"</p>","PeriodicalId":11257,"journal":{"name":"Current topics in behavioral neurosciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in behavioral neurosciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/7854_2024_533","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Neuroscience","Score":null,"Total":0}
引用次数: 0

Abstract

In this chapter, we provide an overview of ethical aspects of psychedelic-assisted treatments in the areas of clinical ethics, research ethics, and at the intersection of psychedelic medicine and society. In contrast to earlier psychedelic research, nowadays medical ethics have been firmly established as a discipline regulating patient-physician relationships which highlight the importance of autonomy, shared decision-making and informed consent in clinical ethics. During and after altered states of consciousness, autonomy is particularly important as participants are in a vulnerable state. In this vulnerable state, both touch and suggestibility are central ethical concerns. In turn, the debate surrounding hallucinogenic and nonhallucinogenic psychedelic substances discusses the importance of altered states of consciousness in general. Of further concern are exceptional training requirements and competencies of psychedelic therapists, as well as the particular context of end-of-life care. Lastly, this section discusses how ethical integrity in clinical treatments can be supported through institutions. In research ethics, inclusivity, research equipoise, and expectation management are key issues in the participation and trials, while open question for the posttrial access to care after psychedelic trials remain. Finally, the chapter addresses the question of equitable access to psychedelic medicine. Furthermore, justice for indigenous communities using psychedelics and the impact of legalization and medicalization of psychedelic substances are pressing ethical concerns amidst the "psychedelic renaissance."

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
迷幻辅助治疗的伦理问题:综述。
在本章中,我们将概述迷幻辅助治疗在临床伦理、研究伦理以及迷幻医学与社会交叉领域的伦理问题。与早期的迷幻药研究不同,如今的医学伦理学已被牢固确立为一门规范病人与医生关系的学科,突出了自主权、共同决策和知情同意在临床伦理学中的重要性。在意识改变状态期间和之后,自主权尤为重要,因为参与者处于脆弱状态。在这种脆弱状态下,触摸和暗示性都是伦理方面的核心问题。反过来,围绕致幻和非致幻迷幻药的争论也讨论了意识改变状态的重要性。更值得关注的是迷幻治疗师的特殊培训要求和能力,以及临终关怀的特殊背景。最后,本节讨论了如何通过机构支持临床治疗中的伦理完整性。在研究伦理方面,包容性、研究平衡和期望管理是参与和试验中的关键问题,而迷幻试验后获得护理的问题仍有待解决。最后,本章讨论了公平获取迷幻药的问题。此外,在 "迷幻药的复兴 "中,为使用迷幻药的原住民社区伸张正义以及迷幻药合法化和医疗化的影响都是亟待解决的伦理问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current topics in behavioral neurosciences
Current topics in behavioral neurosciences Neuroscience-Behavioral Neuroscience
CiteScore
4.80
自引率
0.00%
发文量
103
期刊最新文献
Computational Mechanisms of Information-Seeking in Anxiety. Fear and Anxiety in Schizophrenia: A Focus on Development, Assessment, and Mechanisms. Genetic Tools in Rodents to Study Cannabinoid Functions. Fears Worth Testing Out: A Systematic Review of the Neural Mechanisms of Treatment Outcome for Anxiety-Related Disorders. Sensory Processing and Anxiety: Within and Beyond the Autism Spectrum.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1